Aastrom Update (3-27-13)

 Comments Off on Aastrom Update (3-27-13)
Mar 272013
 
Aastrom Update (3-27-13)

Aastrom (3/27/13) – ASTM Restructures to Focus on Orphan Drug Indication, Lowering BUY and TARGET PRICE – Aastrom dropped a bomb premarket today when new CEO, Dominick Colangelo, announced that the company is shelving their Phase III CLI program and cutting half their workforce after completing a comprehensive strategic review.  ASTM will now focus on […]

Aastrom Update (1-04-13)

 Comments Off on Aastrom Update (1-04-13)
Jan 042013
 
Aastrom Update (1-04-13)

Aastrom has announced that the company’s board of directors has named Dan Orlando interim CEO of Aastrom.  Mr. Orlando, who joined the company as Chief Commercial Officer in August has the experience and skills to handle the additional responsibility. Aastrom’s president and CEO Tim Mayleben is retiring but will remain an active member of the […]

Aastrom Update (11-02-12)

 Comments Off on Aastrom Update (11-02-12)
Nov 022012
 
Aastrom Update (11-02-12)

Aastrom has announced that cell therapy regulatory and development expert Joyce L. Frey-Vasconcells, Ph.D. has been appointed to the company’s Scientific Advisory Board (SAB). Dr. Frey-Vasconcells is considered one of the foremost regulatory experts on cell therapies, tissues and gene therapies.  Dr. Frey-Vasconcells is founder and president of Frey-Vasconcells Consulting LLC and previously served as a […]